**Breast Cancer**

<table>
<thead>
<tr>
<th>Key</th>
<th>Endocrine Therapy</th>
<th>ER/PR-POSITIVE HER2 NEGATIVE</th>
<th>HER2 POSITIVE</th>
<th>“TRIPLE NEGATIVE” EP/PR—NEGATIVE HER2-NEGATIVE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>IRB#6256</td>
<td>IRB#6256</td>
<td>IRB#6256</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular</td>
<td>ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular</td>
<td>ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular</td>
</tr>
</tbody>
</table>

**Pre-Op Therapy**

- **No Trial Currently Available**

**Surgical Therapy**

- **IRB#9340**
  - Phase II breast conservation surgery and radiation therapy study

**Adjuvant Therapy**

- **No Trial Currently Available**

**1st line MBC Therapy**

- **IRB # 16390**
  - A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer

- **IRB # 9076**
  - Phase III study in postmenopausal women that have progressed on or after mTOR therapy

- **IRB#11351**
  - Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced Unresectable Breast Cancer

**2nd line MBC Therapy**

- **No Trial Currently Available**

**3rd line MBC Therapy**

- **IRB#16379 C31006**: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy

- **IRB#15366**
  - Phase 2 Study of ONT-380 vs. Placebo with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
  
  *(Applies to Adjuvant, 1st line and beyond HER2 + MBC therapy)*

- **IRB # 16390**
  - A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer

**“Heavily Pretreated” Therapy**

- **No Trial Currently Available**

- **IRB #15176**
  - A Randomized Open-Label Phase 3 Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC)

12/13/2016  
www.ohsu.edu/cancer